LBRX
NASDAQ · Pharmaceuticals
Lb Pharmaceuticals Inc
$24.21
+0.84 (+3.59%)
Financial Highlights (FY 2025)
Revenue
167.53M
Net Income
47.95M
Gross Margin
49.1%
Profit Margin
28.6%
Rev Growth
-8.2%
D/E Ratio
1.06
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 49.1% | 49.1% | 49.1% |
| Operating Margin | 27.2% | 25.1% | 29.8% |
| Profit Margin | 28.6% | 23.8% | 24.1% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 167.53M | 154.99M | 171.21M |
| Gross Profit | 82.29M | 76.13M | 84.10M |
| Operating Income | 45.52M | 38.93M | 50.95M |
| Net Income | 47.95M | 36.94M | 41.17M |
| Gross Margin | 49.1% | 49.1% | 49.1% |
| Operating Margin | 27.2% | 25.1% | 29.8% |
| Profit Margin | 28.6% | 23.8% | 24.1% |
| Rev Growth | -8.2% | -9.0% | +5.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 263.16M | 225.91M | 228.67M |
| Total Equity | 248.63M | 226.88M | 250.74M |
| D/E Ratio | 1.06 | 1.00 | 0.91 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 61.52M | 61.45M | 59.09M |
| Free Cash Flow | 46.38M | 48.44M | 62.84M |